Latest & greatest articles for memantine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on memantine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on memantine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for memantine

21. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands Hoogveldt B, Rive B, Severens J, Maman K, Guilhaume C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of memantine, relative to standard care, for the treatment of patients with moderate-to-severe Alzheimer’s disease, from a societal perspective. The authors concluded that memantine was more effective and less expensive than usual care, in the Netherlands. The cost-effectiveness

NHS Economic Evaluation Database.2012

22. Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias

Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias Muayqil T, Camicioli R CRD summary This review concluded (...) that combination therapy with memantine and a cholinesterase inhibitor appeared superior to monotherapy in patients with moderate to severe Alzheimer's Disease. They advised a cautious interpretation due to variation in outcome scales and patient characteristics and said it was unclear whether improvements were clinically significant. The authors’ cautious conclusions and recommendations for practice seem appropriate. Authors' objectives To assess the safety and efficacy of combination therapy with memantine

DARE.2012

24. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.

Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. 22236802 2012 02 13 2012 02 21 2015 06 16 1474-547X 379 9815 2012 Feb 11 Lancet (London, England) Lancet Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. 528-36 10.1016/S0140-6736(11)61676-0 Prevalence of Alzheimer's disease in people with Down's syndrome is very high (...) , and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer's disease. Evidence to support treatment with Alzheimer's drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy of memantine on cognition and function in individuals with Down's syndrome. In our prospective randomised double-blind trial, we enrolled adults (>40 years) with karyotypic or clinically diagnosed Down's syndrome

Lancet2012

25. Donepezil and memantine for moderate-to-severe Alzheimer's disease.

Donepezil and memantine for moderate-to-severe Alzheimer's disease. 22397651 2012 03 08 2012 03 16 2016 11 22 1533-4406 366 10 2012 Mar 08 The New England journal of medicine N. Engl. J. Med. Donepezil and memantine for moderate-to-severe Alzheimer's disease. 893-903 10.1056/NEJMoa1106668 Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression (...) to moderate-to-severe disease. We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received

NEJM2012

26. [Responder analyses for memantine in Alzheimer's disease - Rapid report]

[Responder analyses for memantine in Alzheimer's disease - Rapid report] Responderanalysen zu memantin bei alzheimer demenz [Responder analyses for memantine in Alzheimer's disease - Rapid report] Responderanalysen zu memantin bei alzheimer demenz [Responder analyses for memantine in Alzheimer's disease - Rapid report] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation IQWiG. Responderanalysen zu memantin bei alzheimer demenz. [Responder analyses for memantine in Alzheimer's disease - Rapid report] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 84. 2011 Authors' objectives The research question of the present investigation is as follows:
What is the impact of the responder analyses calculated post hoc by Merz and submitted to the G-BA in the fourth quarter of 2010

Health Technology Assessment (HTA) Database.2011

27. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#39

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 11 May 2016 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects recommendations 1.1, 1.2, 1.4, 1.5 and 1.6. Recommendation 1.3 was updated in September 2016 in NICE’s guideline on dementia (CG42

National Institute for Health and Clinical Excellence - Technology Appraisals2011

29. Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures

Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures Article Text Therapeutics Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures Statistics from

Evidence-Based Mental Health2011

30. Memantine for patients with Parkinson`s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

Memantine for patients with Parkinson`s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial 20729148 2010 09 24 2010 10 18 2016 06 22 1474-4465 9 10 2010 Oct The Lancet. Neurology Lancet Neurol Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. 969-77 10.1016/S1474-4422(10)70194-0 Previous studies have suggested that patients with Lewy-body-related dementias (...) might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). Patients (≥50 years of age) with mild to moderate PDD or DLB were recruited from 30 specialist centres in Austria, France, Germany, the UK, Greece, Italy, Spain, and Turkey. They were randomly assigned to placebo

EvidenceUpdates2010

31. Memantine pump device (Ebixa): risk of medication errors

Memantine pump device (Ebixa): risk of medication errors Memantine pump device (Ebixa): risk of medication errors Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Memantine pump device (Ebixa): risk of medication errors From: Published: 10 November 2010 Therapeutic area: and Differences in dose delivery between the pump device and dropper device for memantine. Article date: November 2010 Memantine (Ebixa) is indicated for the treatment of patients with moderate (...) to severe Alzheimer’s disease, and tablets and an oral solution have been available since 2002. A pump device was introduced in March 2010 and replaces memantine oral solution administered by a dropper, which is being phased out by February 2011. Risk of medication errors and accidental overdose Up to 9 August 2010, 7 cases of administration errors with the pump device have been reported worldwide. One patient was admitted to hospital and recovered, and 2 patients experienced somnolence, which is listed

MHRA Drug Safety Update2010

32. Cost effectiveness of memantine in Alzheimer's disease in the UK

Cost effectiveness of memantine in Alzheimer's disease in the UK Cost effectiveness of memantine in Alzheimer's disease in the UK Cost effectiveness of memantine in Alzheimer's disease in the UK Rive B, Grishchenko M, Guilhaume-Goulant C, Katona C, Livingston G, Lamure M, Toumi M, Francois C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study objective was to assess the cost-effectiveness of memantine for treatment of moderate to severe Alzheimer’s disease. The authors concluded that memantine could be regarded as a cost-effective treatment. The study methodology was good and the methods and results were reported adequately. Given the scope of the study, the authors’ conclusions appear valid. Type of economic

NHS Economic Evaluation Database.2010

33. Namenda XR (memantine hydrochloride) extended release capsules

Namenda XR (memantine hydrochloride) extended release capsules Drug Approval Package: Namenda XR (memantine) NDA #022525 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Namenda XR (memantine hydrochloride) 7 mg, 14 mg, 21 mg, & 28 mg extended release capsules Company: Forest Laboratories, Inc. Application No.: 022525 Approval Date: 6/21/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

FDA - Drug Approval Package2010

34. Memantine in patients with Parkinson`s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial

Memantine in patients with Parkinson`s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial 19520613 2009 06 22 2009 08 14 2014 08 15 1474-4422 8 7 2009 Jul The Lancet. Neurology Lancet Neurol Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. 613-8 10.1016/S1474-4422(09)70146-2 Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common (...) forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine in patients with PDD or DLB. We did a parallel-group, 24-week, randomised controlled study of memantine (20 mg per day) versus placebo at four psychiatric and neurological outpatient clinics in Norway, Sweden, and the UK during

EvidenceUpdates2009

35. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia

Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia 19475666 2009 06 03 2009 06 26 2016 11 22 1531-8249 65 5 2009 May Annals of neurology Ann. Neurol. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. 577-85 10.1002/ana.21597 We conducted a randomized, double-blind, placebo-controlled, parallel-group study of both memantine and constraint-induced aphasia therapy (CIAT) on chronic poststroke aphasia followed by an open-label extension (...) phase. Patients were randomized to memantine (20 mg/day) or placebo alone during 16 weeks, followed by combined drug treatment with CIAT (weeks 16-18), drug treatment alone (weeks 18-20), and washout (weeks 20-24), and finally, an open-label extension phase of memantine (weeks 24-48). After baseline evaluations, clinical assessments were done at two end points (weeks 16 and 18), and at weeks 20, 24, and 48. Outcome measures were changes in the Western Aphasia Battery-Aphasia Quotient

EvidenceUpdates2009

36. Memantine for dementia in people with Down syndrome.

Memantine for dementia in people with Down syndrome. BACKGROUND: Alzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome (DS). There is an understanding that an increase in L-glutamate contributes to the pathogenesis of cerebral ischemias and AD. Memantine acts as an antagonist of N-methyl-D-aspartate (NMDA) type receptors, which is thought to reduce abnormal activation of glutamate neurotransmission. It binds with a low affinity to the NMDA receptor and so (...) should not prevent learning and the formation of memory. Memantine can improve cognitive function and slow the decline of AD in the general population over time, and is the subject of this review. It is important to note that people with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g. metabolism and heart rate) and may therefore have different requirements from the general population. OBJECTIVES: To determine

Cochrane2009

38. Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia

Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia Wong CL, Bansback N, Lee PE, Anis AH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the incremental cost-effectiveness of cholinesterase inhibitors and memantine for mild-to-moderate vascular dementia. The authors concluded that, compared with standard care, cholinesterase inhibitors and memantine had small benefits in cognition and were all more costly. If an active treatment was approved, donepezil 10mg was the most cost-effective. There were a few limitations

NHS Economic Evaluation Database.2009

39. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline

Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M CRD summary The review (...) concluded that cholinesterase inhibitors and memantine can result in statistically significant but clinically marginal improvement in measures of cognition and global assessment in patients with dementia. This review was generally well conducted and the authors' conclusions are likely to be reliable. Authors' objectives To determine the effectiveness of cholinesterase inhibitors and the neuropeptide-modifying agent memantine for the treatment of dementia. Searching Cochrane Central Register

DARE.2008

40. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis

Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL CRD summary This review assessed efficacy of memantine on dementia-related behavioural (...) and psychological symptoms and concluded that treatment appeared to be beneficial. Although the authors offered an appropriately cautious conclusion based on the limited evidence presented, the reliability of the review is potentially compromised by bias and error in the search and selection of studies. Authors' objectives To assess the efficacy of memantine as a therapeutic agent for the treatment of behavioural and psychological symptoms related to dementia. Searching MEDLINE, EMBASE, PsycINFO, Cochrane

DARE.2008